SaaS Metrics
Diagnostic Paradigm Shift
Endocrinology
AI Synthesis & Market Narrative
Significant reclassification of common hormonal conditions (PCOS to PMOS) and the identification of undiagnosed hormonal links to resistant hypertension signal a paradigm shift in endocrinology diagnostics and treatment. Substantial investment in endocrinology expertise and research into metabolic-immune interactions further underscore this evolving landscape.
Correlated Linguistic Patterns
["PCOS is now PMOS"
"hormonal condition"
"resistant hypertension"
"elevated cortisol"
"endocrine experts"
"metabolic impairments"]
Driving Media Context
Author Correction: Regulatory T cells in the mouse hypothalamus control immune activation and ameliorate metabolic impairments in high-calorie environments
Nature Communications - Author Correction: Regulatory T cells in the mouse hypothalamus control immune activation and ameliorate metabolic impairments in hig...
Merck Foundation Mark World Hypertension Day 2026 by Providing Close to 1000 Scholarships for Future Cardiovascular Preventive, Cardiology, Diabetes, and Endocrinology Experts From 52 Countries
Merck Foundation Mark World Hypertension Day 2026 by Providing Close to 1000 Scholarships for Future Cardiovascular Preventive, Cardiology, Diabetes, and End...
PCOS is now PMOS. Millions of women might now get better diagnosis, treatment
This change to this common reproductive health issue could lead to better and earlier treatment for 15% of women.
Author Correction: Postprandial lipid metabolism durably enhances T cell immunity
Nature - Author Correction: Postprandial lipid metabolism durably enhances T cell immunity
Hidden Hormonal Condition Found in Nearly One-Third of Resistant Hypertension Patients, Study Says
Nearly one in three patients with resistant hypertension may have an undiagnosed hormonal condition driven by elevated cortisol, according to the largest U.S...
Obesity rise plateaus in developed nations and accelerates in developing nations
Global analysis of obesity trends from 1980 to 2024 in 200 countries and territories using data from 4,050 population-based studies reveals that framing obes...
Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update
This 2026 update integrates emerging trial evidence — particularly for weight loss and liver disease — to refine EASO’s treatment algorithm for obesity manag...
The SIRT3-DsbA-L-TFAM axis restrains cGAS-driven metabolic dysfunction-associated steatohepatitis in male mice
This study identifies a mitochondrial protection pathway that safeguards mitochondrial DNA integrity and limits liver damage. Disrupting this pathway trigger...
NH600001, an etomidate analogue, provides gastrointestinal endoscopy sedation/anesthesia and reduces adrenocortical depression: two randomized controlled trials
The authors conducted two trials to evaluate the efficacy and safety of NH600001, an etomidate derivative, in gastrointestinal endoscopy. The results showed ...
Ionis Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Ionis Pharmaceuticals, Inc.'s Q1 2026 earnings call